Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors. It is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for treatment of solid tumors and hematologic malignancies; and Rebastinib, which is in Phase 1b trial to treat breast cancer, as well as to investigate in combination with chemotherapy and checkpoint inhibitors. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DCPH
CUSIPN/A
Phone781-209-6400
Debt
Debt-to-Equity Ratio0.05
Current Ratio18.44
Quick Ratio18.44
Price-To-Earnings
Trailing P/E Ratio-13.03
Forward P/E Ratio-15.05
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$5.64 per share
Price / Book6.91
Profitability
EPS (Most Recent Fiscal Year)($2.99)
Net Income$-50,280,000.00
Net MarginsN/A
Return on Equity-33.14%
Return on Assets-30.05%
Miscellaneous
Employees65
Outstanding Shares37,660,000
Market Cap$1.48 billion
Deciphera Pharmaceuticals (NASDAQ:DCPH) Frequently Asked Questions
What is Deciphera Pharmaceuticals' stock symbol?
Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."
How were Deciphera Pharmaceuticals' earnings last quarter?
Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) issued its earnings results on Tuesday, August, 7th. The company reported ($0.65) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.03. View Deciphera Pharmaceuticals' Earnings History.
When is Deciphera Pharmaceuticals' next earnings date?
What price target have analysts set for DCPH?
11 equities research analysts have issued 12-month price targets for Deciphera Pharmaceuticals' stock. Their predictions range from $33.00 to $65.00. On average, they anticipate Deciphera Pharmaceuticals' share price to reach $51.1111 in the next twelve months. This suggests a possible upside of 31.2% from the stock's current price. View Analyst Price Targets for Deciphera Pharmaceuticals.
What is the consensus analysts' recommendation for Deciphera Pharmaceuticals?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Deciphera Pharmaceuticals.
What are Wall Street analysts saying about Deciphera Pharmaceuticals stock?
Here are some recent quotes from research analysts about Deciphera Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Deciphera Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib which are in clinical stage. Deciphera Pharmaceuticals, LLC is based in WALTHAM, United States. " (8/14/2018)
- 2. Canaccord Genuity analysts commented, "We continue to expect DCC-2618 durability in GIST cohorts will be a key focus for investors. The Phase 1 is assessing DCC-2618 in 3 separate indications, GIST (cohorts for 2L, 4L, and 5L), advanced systemic mastocytosis (aSM), and glioma/ glioblastoma multiforme (GBM). In November, Deciphera initiated pivotal Invictus trial in 4L GIST and plans to start second Ph3 Intrigue 2L GIST trial by year-end. DCC-2618 has US and EU orphan designation." (8/13/2018)
Who are some of Deciphera Pharmaceuticals' key competitors?
Some companies that are related to Deciphera Pharmaceuticals include GALAPAGOS NV/S (GLPG), Ligand Pharmaceuticals (LGND), United Therapeutics (UTHR), FibroGen (FGEN), Loxo Oncology (LOXO), GW Pharmaceuticals PLC- (GWPH), Ultragenyx Pharmaceutical (RARE), Agios Pharmaceuticals (AGIO), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), Endo International (ENDP), Intercept Pharmaceuticals (ICPT), Madrigal Pharmaceuticals (MDGL), Evotec (EVTCY) and Emergent Biosolutions (EBS).
Who are Deciphera Pharmaceuticals' key executives?
Deciphera Pharmaceuticals' management team includes the folowing people:
- Dr. Michael D. Taylor, Pres, CEO & Director (Age 63)
- Dr. Daniel L. Flynn, Founder & Chief Scientific Officer (Age 63)
- Mr. Christopher J. Morl, Chief Bus. Officer (Age 59)
- Mr. Thomas Patrick Kelly, Chief Financial Officer (Age 47)
- Dr. Stephen B. Ruddy, Chief Technical Officer
When did Deciphera Pharmaceuticals IPO?
(DCPH) raised $101 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Nomura were co-managers.
Has Deciphera Pharmaceuticals been receiving favorable news coverage?
News coverage about DCPH stock has been trending somewhat positive recently, according to Accern. Accern scores the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Deciphera Pharmaceuticals earned a news and rumor sentiment score of 0.18 on Accern's scale. They also assigned news articles about the company an impact score of 46.57 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for Deciphera Pharmaceuticals.
Who are Deciphera Pharmaceuticals' major shareholders?
Deciphera Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Orbimed Advisors LLC (5.33%), Redmile Group LLC (3.92%), FMR LLC (3.14%), Emerald Advisers Inc. PA (1.58%), BlackRock Inc. (1.57%) and Janus Henderson Group PLC (1.49%). View Institutional Ownership Trends for Deciphera Pharmaceuticals.
Which major investors are selling Deciphera Pharmaceuticals stock?
Which major investors are buying Deciphera Pharmaceuticals stock?
DCPH stock was acquired by a variety of institutional investors in the last quarter, including Redmile Group LLC, Janus Henderson Group PLC, Orbimed Advisors LLC, FMR LLC, Vivo Capital LLC, PointState Capital LP, Laurion Capital Management LP and Nexthera Capital LP. View Insider Buying and Selling for Deciphera Pharmaceuticals.
How do I buy shares of Deciphera Pharmaceuticals?
Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Deciphera Pharmaceuticals' stock price today?
One share of DCPH stock can currently be purchased for approximately $38.97.
How big of a company is Deciphera Pharmaceuticals?
Deciphera Pharmaceuticals has a market capitalization of $1.48 billion. The company earns $-50,280,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Deciphera Pharmaceuticals employs 65 workers across the globe.
How can I contact Deciphera Pharmaceuticals?
Deciphera Pharmaceuticals' mailing address is 500 Totten Pond Road, Waltham MA, 02451. The company can be reached via phone at 781-209-6400 or via email at [email protected]
MarketBeat Community Rating for Deciphera Pharmaceuticals (NASDAQ DCPH)
MarketBeat's community ratings are surveys of what our community members think about Deciphera Pharmaceuticals and other stocks. Vote "Outperform" if you believe DCPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DCPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
